Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
President Trump announces deals with Eli Lilly, Novo Nordisk to slash weight loss drug prices
12:49pm, Thursday, 06'th Nov 2025
President Donald Trump announced deals with Eli Lilly and Novo Nordisk to slash the prices of some of their obesity drugs, including upcoming pills, in a landmark effort to expand access to the costly
Trump announces deals with Eli Lilly, Novo Nordisk to slash weight loss drug prices, offer some Medicare coverage
12:04pm, Thursday, 06'th Nov 2025
President Donald Trump announced deals with Eli Lilly and Novo Nordisk to slash the prices of some of their obesity drugs, including upcoming pills, in a landmark effort to expand access to the costly
Trump White House confirms pricing deal with weight-loss-drug giants Eli Lilly, Novo Nordisk
12:04pm, Thursday, 06'th Nov 2025
President Donald Trump's administration confirmed Thursday that it has reached a deal with Eli Lilly and Novo Nordisk that aims to deliver lower prices for their popular GLP-1 drugs to certain Medicar
What is Metsera, the target in Pfizer's and Novo Nordisk's bidding war?
12:01pm, Thursday, 06'th Nov 2025
Pfizer and Novo Nordisk are locked in a bidding war for biotech firm Metsera as the pharmaceutical giants seek to augment their pipeline in the booming weight-loss drug market.
'It's Getting Ugly,' Analyst Says As Pfizer Escalates Its Gloves-Off Fight For Metsera
10:11am, Thursday, 06'th Nov 2025
Metsera stock surged Thursday on reports Pfizer has matched Novo Nordisk's $10 billion bid to buy the obesity-focused biotech.
Wall Street Breakfast Podcast: Government Shutdown Hits New Altitude
06:29am, Thursday, 06'th Nov 2025
FAA will reduce air traffic by 10% across 40 major markets due to staffing shortages from the government shutdown, impacting 3,500-4,000 flights daily. Pfizer (PFE) has matched Novo Nordisk's bid for
Novo Nordisk A/S (NVO) Q3 2025 Earnings Call Transcript
06:21pm, Wednesday, 05'th Nov 2025
Novo Nordisk A/S (NVO) Q3 2025 Earnings Call November 5, 2025 6:30 AM EST Company Participants Jacob Martin Rode - Head of Investor Relations Maziar Doustdar - President, CEO & Member of the Managemen
Pfizer is preparing to sweeten its offer again for Metsera, the weight-loss drug startup at the center of a bidding war that also involves Novo Nordisk.
Novo Nordisk: Problems Compound, But Stock Still Cheap (Rating Downgrade)
03:40pm, Wednesday, 05'th Nov 2025
Novo Nordisk A/S is downgraded to Buy due to emerging risks in the weight loss sector and recent Q3 2025 earnings results. NVO stock's valuation remains historically low, showing signs that a lot of r
Why Novo Nordisk's Q3 Miss Is A Buying Opportunity
03:07pm, Wednesday, 05'th Nov 2025
Novo Nordisk A/S delivered mixed Q3 '25 results, with modest revenue growth but a 27% drop in net profit due to higher financing costs. NVO's GLP-1 franchise, led by Ozempic and Wegovy, faces moderate
Novo Nordisk Q3: Why I'm Not Giving Up Yet
12:08pm, Wednesday, 05'th Nov 2025
Novo Nordisk A/S shares have plunged nearly 70%, yet the company remains a leader in GLP-1 and obesity drugs with strong growth catalysts. Despite fierce competition and a recent reset phase, NVO's Q3
Novo Nordisk Is Seeing Slowing Demand for GLP-1s Wegovy and Ozempic
12:00pm, Wednesday, 05'th Nov 2025
U.S.-listed shares of Novo Nordisk (NVO) fell after the drugmaker scaled back its outlook, citing disappointing demand for its GLP-1 weight loss and diabetes drugs as competition in the sector increas
Novo Nordisk Slides as GLP-1 Fatigue and Pricing Risks Cloud 2025 Outlook
11:54am, Wednesday, 05'th Nov 2025
Shares of Novo Nordisk (NVO) slipped about 1% on Wednesday morning after the company issued a cautious outlook, even though third-quarter revenue exceeded estim
Novo Nordisk Q3 Earnings & Revenues Miss, GLP-1 Drugs Face US Hurdles
11:31am, Wednesday, 05'th Nov 2025
NVO's Q3 profit and revenues miss expectations as Wegovy and Ozempic growth slows amid U.S. compounding and pricing headwinds.
Novo Nordisk slashes full-year sales forecast amid competition in diabetes and obesity markets
11:24am, Wednesday, 05'th Nov 2025
Novo Nordisk (NYSE:NVO) shares moved lower after the drugmaker posted weaker-than-expected revenue growth for Q3 and adjusted its full-year guidance, citing reduced growth expectations for its diabete
